Home » Healthcare Companies Launch Supply Trackers to Help Patients Navigate Shortages of Diabetes and Weight-Loss Drugs

Healthcare Companies Launch Supply Trackers to Help Patients Navigate Shortages of Diabetes and Weight-Loss Drugs

by admin
Healthcare Companies Launch Supply Trackers to Help Patients Navigate Shortages of Diabetes and Weight-Loss Drugs

The demand for diabetes and weight-loss medication from Novo Nordisk and Eli Lilly has elevated considerably, resulting in shortages in provide. In response, healthcare corporations are introducing Supply Trackers to help sufferers in accessing these drugs.

Sales of GLP-1 medication have soared, making Novo Nordisk and Eli Lilly key gamers within the pharmaceutical trade. However, some sufferers have struggled to fill their prescriptions as a result of excessive demand. Various doses of Wegovy, Zepbound, and Mounjaro are at the moment restricted, in keeping with the US Food and Drug Administration (FDA).

Ro, a telehealth platform, has launched a GLP-1 provide tracker to assist sufferers obtain alerts when these medication develop into accessible of their space. This device gives contact info for pharmacies with accessible inventory. Ro founder and CEO Zachariah Reitano emphasised the significance of offering correct and accessible info to sufferers amidst the scarcity.

Eli Lilly can also be engaged on an analogous provide tracker for Zepbound and Mounjaro. The firm’s president of diabetes and weight problems, Patrik Jonsson, highlighted their dedication to rising the supply of medicines and offering well timed info to customers.

Both Novo Nordisk and Eli Lilly have invested billions in increasing manufacturing of weight reduction medication. However, sufferers should face shortages within the quick time period. Jonsson acknowledged the challenges of assembly the wants of hundreds of thousands of Americans with weight problems, emphasizing the significance of collaboration and innovation in addressing provide constraints.

This article relies on a report from Quartz and highlights efforts by healthcare corporations to deal with the rising demand for GLP-1 medication.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy